share_log

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

Benzinga Real-time News ·  Mar 22, 2021 19:03

— Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated —

— Maintained Safety and Tolerability of RP-L301 up to 6-months Post-treatment —

— Long-Term Data on Track for 2H2021 —

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment